BIONIK has received regulatory approval in South Korea and secured the first sale of BIONIK’s InMotion robotic technology.
BIONIK Laboratories (OTCQB:BNKL) has received regulatory approval in South Korea and its exclusive distributor Curexo secured the first sale for BIONIK’s InMotion robotic technology in the country, out of Curexo’s existing inventory.
As quoted in the press release:
BIONIK received notice of regulatory approval for its InMotion® ARM from the South Korean Ministry of Food and Drug Safety on January 08, 2020, representing a significant step toward the penetration of Asian markets for the company. Just days later, Curexo, a recognized leader in medical device distribution and BIONIK’s exclusive distribution partner in South Korea, received its first purchase order for an InMotion® ARM system from SeoSong Rehabilitation Hospital, a new university rehabilitation nursing hospital expected to open on March 1, 2020. Both the regulatory approval and purchase order were led by Curexo.